Comparison of 1.1 gbq and 2.2 gbq131I activities in patients with low-risk differentiated thyroid cancer requiring postoperative iodine-131 therapy.

被引：0

作者：

Campenni, A. ^{[1
]}

Ruggeri, R. ^{[1
]}

Garo, M. ^{[2
]}

Raffa, A. ^{[1
]}

Siracusa, M. ^{[1
]}

Restuccia, G. ^{[1
]}

Rappazzo, A. ^{[1
]}

Rosarno, H. ^{[1
]}

Nicocia, A. ^{[1
]}

Cardile, D. ^{[1
]}

Ovcaricek, P. Petranovic ^{[3
]}

Baldari, S. ^{[1
]}

Giovanella, L. ^{[4
,5
]}

机构：

[1] Osped Gaetano Martino, Messina, Italy

[2] Mathsly Res, Rome, Italy

[3] Univ Hosp Ctr Sestre Milosrdnice, Zagreb 10000, Croatia

[4] Ente Osped Cantonale, Clin Nucl Med, CH-6500 Bellinzona, Switzerland

[5] Ente Osped Cantonale, Imaging Inst Southern Switzerland, Competence Ctr Thyroid Dis, CH-6500 Bellinzona, Switzerland

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

OP-392

引用

页码：S171 / S172

页数：2

共 50 条

[21] Outcome of patients treated with more than 33.3 GBq (900 mCi) 131I for metastatic differentiated thyroid cancer.
Sheikh, A
Wang, W
Pearson, JR
Robbins, R
Larson, SM
JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 175P - 175P
[22] A comparison of the frequency, duration and severity of salivary side effects in differentiated thyroid cancer patients treated with <1.85 GBq (50 mCi) versus. 7.4 GBq (200 mCi) I-131 therapy: an analysis of the ThyCa national survey
Di Wu
Lima, Cristiane Jeyce Gomes
Turner, Deniek
Hall, Jordan
Khorjekar, Gauri
Zeymo, Alexander
Brennan, Michael
McIver, Bryan
Bloom, Gary
Van Nostrand, Douglas
JOURNAL OF NUCLEAR MEDICINE, 2017, 58
[23] Should "low-risk" thyroid cancer patients with residual thyroglobulin be retreated with iodine 131?
Hindie, E.
Zanotti-Fregonara, P.
Duron, F.
Keller, I.
Moretti, J.
Devaux, J.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S329 - S330
[24] Close contact restriction periods for patients who have received iodine-131 therapy for differentiated thyroid cancer
Forster, Jake C.
Badger, Daniel
Hickson, Kevin J.
JOURNAL OF RADIOLOGICAL PROTECTION, 2023, 43 (02)
[25] Do all patients with differentiated thyroid cancer benefit from 131I therapy.
McDougall, IR
JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 324P - 324P
[26] Impact of extrathyroidal autoimmune diseases on clinical features and the efficacy of Iodine-131 therapy in patients with differentiated thyroid cancer
Long, Ya-hong
Li, Na
Ma, Le
Zhang, Wan-chun
IMMUNITY INFLAMMATION AND DISEASE, 2024, 12 (09)
[27] Radiodine uptake in thyroid remnants in patients with differentiated thyroid cancer:: A comparison between very-low 131I diagnostic dose and high 131I therapy activities
Azevedo-Silva, F.
Cavaco, A.
Freitas, D.
Isidoro, J.
Vieira, F.
Costa, G.
Pedroso-Lima, J.
Ferrer-Antunes, A. I.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S230 - S230
[28] Is 740 MBq of iodine 131 (131I) an ablative dose for thyroid remnants, after total thyroidectomy for low risk group patients with differentiated thyroid cancer ?
Cuif-Job, A.
Fieffe, S.
Kere, D.
Wernert, R.
Pochart, J.
Schvartz, C.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S222 - S223
[29] Comparing High and Low dose I-131 Therapy in Intermediate and Low Risk Differentiated Thyroid Cancer Patients
Yasmin, T.
Adnan, S.
Younis, M. N.
Shahid, A.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S664 - S665
[30] Outpatient Thyroid Remnant Ablation Using Repeated Low 131-Iodine Activities (740 MBq/20 mCi x 2) in Patients with Low-Risk Differentiated Thyroid Cancer
Clerc, Jerome
Bienvenu-Perrard, Marie
de Malleray, Caroline Pichard
Dagousset, Francoise
Delbot, Thierry
Dreyfuss, Marc
Groussin, Lionel
Marlowe, Robert J.
Leger, Francoise Aubene
Chevalier, Alain
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03): : 871 - 880

← 1 2 3 4 5 →